In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your area of specialty? 

Question Title

* 3. How many years have you been in practice?

Question Title

* 4. Please select the option that best describes your practice setting:

Question Title

* 5. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 6. After participating in this activity, how confident are you in the management of patients with ALL in your practice?

Question Title

* 7. OA is a 13-year-old male diagnosed with B-cell ALL. 
  • His white blood cell count at diagnosis was 40 x109/L and he did not have CNS involvement.
  • He received induction on UKALL 2003 and his day 8 bone marrow biopsy showed a rapid early response with 5% blasts.
  • At the end of induction his bone marrow biopsy showed MRD < 0.01% and he proceeded with reduced-intensity therapy with 1 delayed intensification followed by maintenance therapy for 2.5 years.
  • At a follow-up appointment 5 years after his diagnosis his parents would like to understand the likelihood of long-term overall survival. 
Which of the following is the most appropriate response?

Question Title

* 8. After 10 years of follow-up in the UKALL 2003 trial, augmentation of treatment intensity in children and adolescent young adult (AYA) with acute lymphoblastic leukemia (ALL) and minimal residual disease (MRD) > 0.01% at the end of induction was associated with which of the following outcomes?

Question Title

* 9. Dosing pegaspargase at 500 U/m2 in patients with elevated risk for hepatoxicity on the GMALL Trial 8/2013 was associated with which of the following outcomes?

Evaluation Form
In order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety.

Question Title

* 10. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 11. Which of the following best describes the impact of this activity on your performance?

Question Title

* 12. Which new strategies/skills/information will you apply to your area of practice?

Question Title

* 13. What barriers do you see to making changes in your practice?

Question Title

* 14. After participating in today’s activity, I am now better able to:

  Strongly agree Agree Neutral Disagree Strongly disagree
Review recently presented clinical trial data in adults, children, and adolescents/young adults with acute lymphoblastic leukemia basing treatment decisions on minimal-residual disease
Review recently presented clinical trial data on dosing strategies for pegaspargase in adults with acute lymphoblastic leukemia / lymphoblastic lymphoma with risk factors for hepatotoxicity

Question Title

* 15. The following faculty presenter effectively presented the material:

  Strongly agree Agree Neutral Disagree Strongly disagree
Lori Muffly, MD, MS
Marlise Luskin, MD, MSCE

Question Title

* 16. The content presented:

  Strongly agree Agree Neutral Disagree Strongly disagree
Enhanced my current knowledge base
Addressed my most pressing questions
Promoted improvements or quality in health care
Was scientifically rigorous and evidence based
Avoided commercial bias or influence

Question Title

* 17. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 18. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 19. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

Question Title

* 20. Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

Question Title

* 21. I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 CreditTM.

( Privacy & Cookie Notice

T